On Pharma’s incentives: cures vs treatments.

“I’ve been in and around the pharma industry for nearly 30 years, and I’ve spent time in gene therapy/gene editing where the one-time cure model dominates. Some thoughts on chronic vs. curative dosing and why a curative therapy is likely worth less:…” ~ learn more